Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-08-18
2000-11-14
Lambkin, Deborah C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514250, 514255, 514289, A61K 31495, A61K 3144
Patent
active
061470759
ABSTRACT:
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
REFERENCES:
patent: 3962440 (1976-06-01), St. Clair et al.
patent: 3992378 (1976-11-01), St. Clair et al.
patent: 4659713 (1987-04-01), Hass
patent: 4803270 (1989-02-01), Takemoto
patent: 4812458 (1989-03-01), Honore et al.
patent: 4889855 (1989-12-01), Jacobsen et al.
patent: 4948794 (1990-08-01), Honore et al.
patent: 4975430 (1990-12-01), Jahr et al.
patent: 4977155 (1990-12-01), Jacobsen et al.
patent: 5026704 (1991-06-01), Honore et al.
patent: 5055465 (1991-10-01), Davey
patent: 5057516 (1991-10-01), Jacobsen et al.
patent: 5061706 (1991-10-01), Honoreee et al.
patent: 5081123 (1992-01-01), Honoreet al.
patent: 5166155 (1992-11-01), Jorgensen et al.
patent: 5196421 (1993-03-01), McQuaid et al.
patent: 5268378 (1993-12-01), Baker et al.
patent: 5283244 (1994-02-01), Sakamoto et al.
patent: 5308845 (1994-05-01), Honoreet al.
patent: 5352683 (1994-10-01), Mayer et al.
patent: 5514680 (1996-05-01), Weber et al.
patent: 5620979 (1997-04-01), Weber et al.
patent: 5622952 (1997-04-01), Weber et al.
patent: 5631373 (1997-05-01), Cai et al.
Andreasen, M., et al., "Effects of New Non-N-Methyl-D-Aspartate Antagonists on Synaptic Transmission in the in vitro Rat Hippocampus," J. Physiol. 414:317-336 (1989).
Allison, C.G., et al., "Polyfluoroheterocyclic Compounds Part XX. Preparation and Nucleophilic Substitution of Hexafluoroquinoxaline," J. Fluorine Chem. 1(1):59-67 (1971).
Bigge, C.F., "Structural Requirements for the Development of Potent N-Methyl-D-Aspartic Acid (NMDA) Receptor Antagonists," Biochem. Pharm. 45(8):1547-1561 (Apr. 1993).
Birch, P.J., et al., "FG9065 and FG9041 antagonise responses to NMDA via an Action at the strychnine-insensitive glycine receptor," Br. J. Pharmacol. 95:758P (1988).
Carling, R.W., et al., "Anticonvulsant Activity of Glycine-Site NMDA Antagonists. 2. Trans 2-Carboxy-4-Substituted Tetrahydroquinolines," Bioorganic & Medicinal Chem. Lett. 3(1):65-70 (Jan. 1993).
Carling, R.W., et al., "3-Nitro-3,4-dihydro-2(1H)-quinolines. Excitatory Amino Acid Antagonists Acting at Glycine-Site NMDA and (RS)-.alpha.-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors," J. Med. Chem. 36(22):3397-3408 (Oct. 1993).
Cheeseman, G.W.H., "Quinoxalines and Related Compounds. Part VI. Substitution of 2,3-Dihydroxyquinoxaline and its 1,4-Dimethyl Derivative," J. Chem. Soc. 223:1170-1176 (1962).
Danysz, W., and Wrobleski, J.T., "Amnesic Properties of Glutamate Receptor Antagonists," Neurosci. Res. Comm. 5(1):9-18 (1989).
Davies, S.N., and Collinridge, G.L., "Quinoxalinediones as Excitatory Amino Acid Antagonists in the Vertebrate Central Nervous System," Int. Rev. Neurobiol. 32:281-303 (1990).
Drejer, J., and Honore, T., "New quinoxalinediones show potent antagonism of quisqualate responses in cultured mouse cortical neurons," Neuroscience Lett. 87:104-108 (1988).
Epperson, J.R., et al., "Synthesis and Excitatory Amino Acid Pharmacology of Some Novel Quinoxalinediones," Bioorganic & Medicinal Chem. Lett. 3(12):2801-2804 (Dec. 1993).
Fletcher, E.J., and Lodge, D., "Glycine reverses antagonism of N-methyl-D-aspartate (NMDA) by 1-hydroxy-3-aminopyrrolidone-2 (HA-966) but not by D-2-amino-5-phophonovalerate (D-AP5) on rat cortical slices," Eur. J. Pharmacol. 151:161-162 (1988).
Fletcher, E.J., et al., "Quinoxalinediones selectively block quisqualate and kainate receptors and synaptic events in rat neocortex and hippocampus and frog spinal cord in vitro," Br. J. Pharmacol. 95:585-597 (1988).
Frandsen, A., et al., "Direct Evidence That Excitotoxicity in Cultured Neurons Is Mediated via N-Methyl-D-Aspartate (NMDA) as well as Non-NMDA Receptors," J. Neurochem. 53(1):297-299 (1989).
Frenk, H., et al., "Absence of Side-Effects in the Anticonvulsant Action of Cortically Applied Antagonists of N-Methyl-D-Aspartate," Brain Res. 373:222-226 (1986).
Hays, S.J., et al., "N-Sulfonyl Derivatives of 6,7-Dichloro-3,4-dihydro-3-oxo-quinoxalinecarboxylate as Glycine-Site NMDA and AMPA Antagonists," Bioorganic & Medicinal Chem. Lett. 3(1):77-80 (Jan. 1993).
Honore, T., et al., "Quinoxalinediones: Potent Competitive Non-NMDA Glutamate Receptor Antagonists," Science 241:701-703 (1988).
Honore,T., et al., "Preparation and resting of 2,3(1H,4H)-quinoxalinediones as neuroleptics," Chem. Abstr. 111:232859a (1989).
Honore, T., et al., "Quinoxalinediones. Non-N-Methyl-D-aspartate Receptor Antagonists as Potential Drug Candidates," in Excitatory Amino Acids, Meldrum et al., eds. New York: Raven Press, Ltd., pp. 451-460 (1991).
Honore, T., et al., "Preparation and use of neuroleptic quinoxaline compounds," Chem. Abstr. 114:81885q (1991).
Horner, L., and Schwenk, U., "Derivatives of quinoxaline as isosteres of the pteridines," Chem. Abstr. 48:2692-2693 (1954).
Joergensen, A.S., et al., "Preparation of 1-carboxyalkyl-2,3-dioxoquinoxalines as glycine antagonists," Chem. Abstr. 115:280059u (1991).
Jurson, P.A., and Freed, W.J., "A Slight Anticonvulsant Effect of CNQX and DNQX as Measured by Homocysteine- and Quisqualate-Induced Seizures," Pharmacological Biochemistry and Behavior 36:177-181 (1990).
Kay, C.D., and Ikeda, H., "The quinoxalinediones antagonise the visual firing of sustained retinal ganglion cells," Eur. J. Pharmacol. 164:381-384 (1989).
Kemp, J.A., and Leeson, P.D., "The glycine site of the NMDA receptor--five years on," TiPS 14:20-25 (Jan. 1993).
Kessler, M., et al., "Quinoxaline derivatives are high-affinity antagonists of the NMDA receptor-associated glycine sites," Brain Res. 489:377-382 (1989).
Kessler, M, et al., "A Glycine Site Associated with N-Methyl-D-Aspartic Acid Receptors: Characterization and identification of a New Class of Antagonists," J. Neurochem. 52(4):1319-1328 (1989).
Kleckner, N.W., and Dingledine, R., "Selectivity of Quinoxalines and Kynurenines as Antagonists of the Glycine Site on N-Methyl-D-aspartate Receptors," Molec. Pharmacol. 36:430-436 (1989).
Kulagowski, J.J., et al., "3'-(Arylmethyl)- and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor," J. Med. Chem. 37(10):1402-1405 (1994).
Leeson, P.D., et al., "Kynurenic Acid Derivatives. Structure-Activity Relationships for Excitatory Amino Acid Antagonism and Identification of Potent and Selective Antagonists at the Glycine Site on the N-Methyl-D-aspartate Receptor," J. Med. Chem. 34(4):1243-1252 (1991).
Leeson, P.D., "Glycine-Site-N-Methyl-D-Aspartate Receptor Antagonists," in Drug Design for Neruroscience, A.P. Kozikowski, ed. New York: Raven Press, Ltd., pp. 339-381 (Jul. 1993).
Leeson, P.D., et al., "Amino Acid Bioisosteres: Design of 2-Quinolone Derivatives as Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists," Bioorganic & Medicinal Chem. Lett. 3(2):299-304 (Feb. 1993).
Leeson, P.D., and Iversen, L.L., "The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential," J. Med. Chem. 37(24):4053-4067 (1994).
Lester, R.A.J., et al., "Interaction of 6-Cyano-7-nitroquinoxaline-2,3-dione with the N-Methyl-D-aspartate Receptor-Associated Glycine Binding Site," Molec. Pharmacol. 35:565-570 (1989).
Littman, T., et al., "The quinoxalinediones DNQX, CNQX and two related congeners suppress hair cell-to-auditory nerve transmission," Hearing Res. 40:45-54 (1989).
Lodge, D., and Jones, M.G., "Evidence for Glutamate Receptor Subtypes from in vivo Electrophysiology: Studies with HA-966, Quinoxalinediones and Philanthotoxin," in Excitatory Amino Acids
Cai Sui Xiong
Keana John F. W.
Kher Sunil
Weber Eckard
Cocensys Inc.
Lambkin Deborah C.
State of Oregon Acting by and Through the Oregon State Board of
The Regents of the University of California
LandOfFree
Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065649